Edition:
United Kingdom

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

228.54USD
16 Jan 2018
Change (% chg)

$0.83 (+0.36%)
Prev Close
$227.71
Open
$227.98
Day's High
$230.04
Day's Low
$226.62
Volume
602,146
Avg. Vol
346,610
52-wk High
$230.04
52-wk Low
$169.23

Latest Key Developments (Source: Significant Developments)

BD Statement On FDA Warning Letter For Preanalytical Systems Business Unit
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Becton Dickinson And Co ::BD STATEMENT ON FDA WARNING LETTER FOR PREANALYTICAL SYSTEMS BUSINESS UNIT.BECTON DICKINSON - AFTER FDA INSPECTION IN JULY, TOOK ACTION THAT CO BELIEVED FULLY ADDRESSED AGENCY'S INSPECTIONAL OBSERVATIONS.BECTON DICKINSON - "CAREFULLY REVIEWING" FDA'S FEEDBACK OUTLINED IN LETTER WITH HIGHEST SENSE OF URGENCY, TO PROVIDE FULL RESPONSE ON OR BEFORE FEB 1.  Full Article

FDA Issues Warning Letter To Becton Dickinson & Co
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - U.S. Food and Drug Administration::FDA WARNS BECTON DICKINSON & COMPANY OF SIGNIFICANT VIOLATIONS OF THE LAW AS PART OF ONGOING INVESTIGATION INTO LEAD TESTING ISSUES‍​.U.S. FDA SAYS BECTON DICKINSON'S VIOLATIONS INCLUDE MARKETING MODIFIED VERSIONS OF CERTAIN BD VACUTAINER BLOOD COLLECTION TUBES WITHOUT REQUIRED APPROVAL.FDA SAYS INSPECTION SHOWED BD VIOLATED LAW BY MAKING SIGNIFICANT CHANGE TO SOME OF ITS DEVICES WITHOUT NOTIFYING FDA.‍FDA​ SAYS VIOLATIONS WERE DISCOVERED THROUGH AN INSPECTION OF BECTON DICKINSON ’S NEW JERSEY FACILITY.FDA SAYS BECTON DICKINSON HAS UNTIL FEB 1, 2018 TO NOTIFY FDA ABOUT SPECIFIC STEPS CO HAS TAKEN TO ADDRESS FDA IDENTIFIED VIOLATIONS.FDA - BD DID NOT ADDRESS COMPLAINT OF VARIABILITY IN RESULTS WHEN SOME BD VACUTAINER BLOOD COLLECTION TUBES WERE USED WITH MAGELLAN DIAGNOSTICS’ LEADCARE TEST SYSTEMS.  Full Article

BD Announces Extension Of Exchange Offers And Consent Solicitations For C. R. Bard Inc Notes
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Becton Dickinson And Co ::BD ANNOUNCES EXTENSION OF EXCHANGE OFFERS AND CONSENT SOLICITATIONS FOR C. R. BARD, INC. NOTES.BECTON DICKINSON - EXTENDING EXPIRATION DATE OF EXCHANGE OFFERS AND CONSENT SOLICITATIONS TO 5:00 P.M., NEW YORK CITY TIME, DEC 28, 2017.  Full Article

BD Issues Statement On FTC Clearance Of Bard Acquisition
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Becton Dickinson and Co::BD STATEMENT ON FTC CLEARANCE OF BARD ACQUISITION.EXPECT BARD DEAL WILL CLOSE IN DECEMBER, PENDING APPROVAL BY CHINA MINISTRY OF COMMERCE, SOME OTHER CONDITIONS.  Full Article

BD board increases dividend
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Becton Dickinson And Co ::BD board increases dividend.Becton Dickinson And Co - ‍declared a quarterly dividend of $0.75 per common share, an increase of 2.7 percent from previous quarter​.  Full Article

Merit Medical signs purchase agreement with BD for divestment assets
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Merit Medical Systems Inc ::Merit Medical signs purchase agreement with BD for divestment assets.Merit Medical Systems Inc - ‍purchase price for product lines and related assets to be acquired is $100 million​.Merit Medical Systems Inc - ‍purchase price for product lines and related assets to be acquired is $100 million​.Merit Medical Systems- ‍intends to finance acquisition at closing through borrowings which are currently available under its revolving credit facility​.Merit Medical Systems Inc - ‍transaction is also expected to expand operating margins and increase cash flow​.Merit - ‍has signed asset purchase agreement with bd to acquire certain assets which bd proposes to sell in connection with acquisition of C.R. Bard​.Merit Medical Systems Inc - ‍transaction is expected to be accretive to both GAAP and non-GAAP earnings in 2018 for Merit's shareholders​.Merit Medical Systems Inc - ‍expects acquisition to provide $0.10-$0.19 in adjusted non-GAAP earnings per share accretion in fiscal year 2018​.Merit Medical Systems Inc - ‍ expects deal to be accretive by 50-120 basis points to co's adjusted gross margins over a period of six to twelve months​.  Full Article

Becton Dickinson says Q4 earnings per share $1.24
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Becton Dickinson And Co -:BD announces results for 2017 fourth fiscal quarter and full year; provides fiscal 2018 guidance.Q4 earnings per share $1.24.Q4 revenue $3.166 billion versus I/B/E/S view $3.15 billion.Q4 earnings per share view $2.37 -- Thomson Reuters I/B/E/S.Q4 adjusted earnings per share $2.40.Sees FY 2018 earnings per share $10.55 to $10.65 including items.Sees FY 2018 revenue $12.09 billion.Becton Dickinson And Co - ‍acquisition of C.R. Bard is on-track with an expected closing date in fourth calendar quarter of 2017​.Becton Dickinson-‍on stand-alone basis, co expects FY 2018 revenues to increase 5.0 to 6.0 percent as reported, or 4.0 to 5.0 percent on currency-neutral basis​.  Full Article

U.S. court denies motion to reconsider Becton, Dickinson and Co. judgment
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Retractable Technologies Inc ::Retractable Technologies Inc says on Oct 27, court denied motion to alter or amend earlier judgment in co's case against Becton, Dickinson and Co​.  Full Article

BD statement on European Commission conditional clearance of Bard acquisition
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Becton Dickinson and Co :BD statement on European Commission conditional clearance of bard acquisition.Says continue to expect that BD and Bard transaction will close in fourth calendar quarter of 2017​.Says ‍"committed" to divesting certain assets to satisfy conditions requested by European Commission​ for Bard deal.  Full Article

Becton Dickinson announces early access program for BD Resolve single-cell analysis platform
Monday, 13 Feb 2017 

Becton Dickinson And Co : BD announces early access program for bd resolve™ single-cell analysis platform .Becton dickinson and co- plans full commercial launch of bd resolve platform by early fall 2017.  Full Article